897 related articles for article (PubMed ID: 31641008)
1. A TAZ-ANGPTL4-NOX2 Axis Regulates Ferroptotic Cell Death and Chemoresistance in Epithelial Ovarian Cancer.
Yang WH; Huang Z; Wu J; Ding CC; Murphy SK; Chi JT
Mol Cancer Res; 2020 Jan; 18(1):79-90. PubMed ID: 31641008
[TBL] [Abstract][Full Text] [Related]
2. The Hippo Pathway Effector TAZ Regulates Ferroptosis in Renal Cell Carcinoma.
Yang WH; Ding CC; Sun T; Rupprecht G; Lin CC; Hsu D; Chi JT
Cell Rep; 2019 Sep; 28(10):2501-2508.e4. PubMed ID: 31484063
[TBL] [Abstract][Full Text] [Related]
3. Hippo pathway effectors YAP/TAZ as novel determinants of ferroptosis.
Yang WH; Chi JT
Mol Cell Oncol; 2020; 7(1):1699375. PubMed ID: 31993503
[TBL] [Abstract][Full Text] [Related]
4. Roles of YAP/TAZ in ferroptosis.
Magesh S; Cai D
Trends Cell Biol; 2022 Sep; 32(9):729-732. PubMed ID: 35701310
[TBL] [Abstract][Full Text] [Related]
5. TAZ Regulates the Cisplatin Resistance of Epithelial Ovarian Cancer Cells via the ANGPTL4/SOX2 Axis.
Li C; Wang Q; Luo Y; Xiang J
Anal Cell Pathol (Amst); 2022; 2022():5632164. PubMed ID: 36247876
[TBL] [Abstract][Full Text] [Related]
6. Regulation of ferroptosis in cancer cells by YAP/TAZ and Hippo pathways: The therapeutic implications.
Sun T; Chi JT
Genes Dis; 2021 May; 8(3):241-249. PubMed ID: 33997171
[TBL] [Abstract][Full Text] [Related]
7. The Hippo Pathway Effector YAP Promotes Ferroptosis via the E3 Ligase SKP2.
Yang WH; Lin CC; Wu J; Chao PY; Chen K; Chen PH; Chi JT
Mol Cancer Res; 2021 Jun; 19(6):1005-1014. PubMed ID: 33707306
[TBL] [Abstract][Full Text] [Related]
8. YAP/TAZ-mediated regulation of laminin 332 is enabled by β4 integrin repression of ZEB1 to promote ferroptosis resistance.
Goel HL; Karner ER; Kumar A; Mukhopadhyay D; Goel S; Mercurio AM
J Biol Chem; 2024 Apr; 300(4):107202. PubMed ID: 38508310
[TBL] [Abstract][Full Text] [Related]
9. A novel role for microRNA-129-5p in inhibiting ovarian cancer cell proliferation and survival via direct suppression of transcriptional co-activators YAP and TAZ.
Tan G; Cao X; Dai Q; Zhang B; Huang J; Xiong S; Zhang Yy; Chen W; Yang J; Li H
Oncotarget; 2015 Apr; 6(11):8676-86. PubMed ID: 25895125
[TBL] [Abstract][Full Text] [Related]
10. Hypoxic conditions differentially regulate TAZ and YAP in cancer cells.
Yan L; Cai Q; Xu Y
Arch Biochem Biophys; 2014 Nov; 562():31-6. PubMed ID: 25078107
[TBL] [Abstract][Full Text] [Related]
11. New insights into the ambivalent role of YAP/TAZ in human cancers.
Luo J; Deng L; Zou H; Guo Y; Tong T; Huang M; Ling G; Li P
J Exp Clin Cancer Res; 2023 May; 42(1):130. PubMed ID: 37211598
[TBL] [Abstract][Full Text] [Related]
12. A Division of Labor between YAP and TAZ in Non-Small Cell Lung Cancer.
Shreberk-Shaked M; Dassa B; Sinha S; Di Agostino S; Azuri I; Mukherjee S; Aylon Y; Blandino G; Ruppin E; Oren M
Cancer Res; 2020 Oct; 80(19):4145-4157. PubMed ID: 32816858
[TBL] [Abstract][Full Text] [Related]
13. An Imbalance in TAZ and YAP Expression in Hepatocellular Carcinoma Confers Cancer Stem Cell-like Behaviors Contributing to Disease Progression.
Hayashi H; Higashi T; Yokoyama N; Kaida T; Sakamoto K; Fukushima Y; Ishimoto T; Kuroki H; Nitta H; Hashimoto D; Chikamoto A; Oki E; Beppu T; Baba H
Cancer Res; 2015 Nov; 75(22):4985-97. PubMed ID: 26420216
[TBL] [Abstract][Full Text] [Related]
14. TAZ Protein Accumulation Is Negatively Regulated by YAP Abundance in Mammalian Cells.
Finch-Edmondson ML; Strauss RP; Passman AM; Sudol M; Yeoh GC; Callus BA
J Biol Chem; 2015 Nov; 290(46):27928-38. PubMed ID: 26432639
[TBL] [Abstract][Full Text] [Related]
15. Non-hippo kinases: indispensable roles in YAP/TAZ signaling and implications in cancer therapy.
Zhu J; Wu T; Lin Q
Mol Biol Rep; 2023 May; 50(5):4565-4578. PubMed ID: 36877351
[TBL] [Abstract][Full Text] [Related]
16. YAP/TAZ and ATF4 drive resistance to Sorafenib in hepatocellular carcinoma by preventing ferroptosis.
Gao R; Kalathur RKR; Coto-Llerena M; Ercan C; Buechel D; Shuang S; Piscuoglio S; Dill MT; Camargo FD; Christofori G; Tang F
EMBO Mol Med; 2021 Dec; 13(12):e14351. PubMed ID: 34664408
[TBL] [Abstract][Full Text] [Related]
17. DDR2 upregulation confers ferroptosis susceptibility of recurrent breast tumors through the Hippo pathway.
Lin CC; Yang WH; Lin YT; Tang X; Chen PH; Ding CC; Qu DC; Alvarez JV; Chi JT
Oncogene; 2021 Mar; 40(11):2018-2034. PubMed ID: 33603168
[TBL] [Abstract][Full Text] [Related]
18. The Hippo Effector Transcriptional Coactivator with PDZ-Binding Motif Cooperates with Oncogenic β-Catenin to Induce Hepatoblastoma Development in Mice and Humans.
Zhang S; Zhang J; Evert K; Li X; Liu P; Kiss A; Schaff Z; Ament C; Zhang Y; Serra M; Evert M; Chen N; Xu F; Chen X; Tao J; Calvisi DF; Cigliano A
Am J Pathol; 2020 Jul; 190(7):1397-1413. PubMed ID: 32283103
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of TAZ promotes cell proliferation, migration and epithelial-mesenchymal transition in ovarian cancer.
Chen G; Xie J; Huang P; Yang Z
Oncol Lett; 2016 Sep; 12(3):1821-1825. PubMed ID: 27588129
[TBL] [Abstract][Full Text] [Related]
20. Transcriptomic and functional analysis of ANGPTL4 overexpression in pancreatic cancer nominates targets that reverse chemoresistance.
Gordon ER; Wright CA; James M; Cooper SJ
BMC Cancer; 2023 Jun; 23(1):524. PubMed ID: 37291514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
